AUSTIN, Texas - Natera, Inc. (NASDAQ: NASDAQ:NTRA), a company specializing in cell-free DNA testing, has announced that its Prospera Heart and Prospera Kidney tests have gained commercial insurance coverage from a major Blue Cross Blue Shield (BCBS) plan in the United States. This development, revealed today, marks a significant expansion in access to Natera's non-invasive tests for organ transplant recipients.
The newly covered Prospera tests are designed to monitor the health of transplanted organs by measuring levels of donor-derived cell-free DNA in the blood, a method that can indicate the risk of organ rejection. The tests will now be available to a wider range of patients with commercial insurance, complementing the existing Medicare coverage for heart, kidney, and lung transplant patients.
Bernie Tobin, general manager of organ health at Natera, expressed enthusiasm for the policy change, highlighting the importance of early detection of potential graft issues for improving patient outcomes. The company's commitment to supporting transplant patients is underscored by its extensive research, including 39 peer-reviewed publications and ongoing multi-site, prospective studies.
The Prospera tests utilize Natera's proprietary technology to offer a non-invasive and accurate alternative to traditional biopsies. While the tests have not received FDA clearance or approval, they have been analytically and clinically validated and are performed in Natera's CLIA-certified laboratory.
Natera, recognized as a leader in the field of cell-free DNA testing, focuses on applications in oncology, women's health, and organ health. The company's goal is to integrate personalized genetic testing into standard care practices to enable early interventions and promote longer, healthier lives.
The information in this article is based on a press release statement from Natera, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.